Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Neratinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Puma Biotechnology
- 31 Aug 2018 Biomarkers information updated
- 26 Jun 2018 Status changed from active, no longer recruiting to completed.
- 09 Dec 2017 Results (n=966) of pooled subgroup analysis of NCT00445458, NCT00706030, NCT00398567, NCT00915018, NCT00741260 and NCT00300781trials assessing safety and efficacy of neratinib therapy in Asian patients from China, Hong Kong, Japan, Korea, Malaysia, Singapore, and Taiwan presented at the 40th Annual San Antonio Breast Cancer Symposium